Key facts
- It has raised $10K; the latest was Seed Round ($10K) in Jan 2025.
- Notable investors include Soma Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cathedral Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cathedral Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cathedral Therapeutics
Developer of a novel technology method intended for gene therapies. The company offers an approach using protein vaults to protect adeno-associated viruses from antibodies, enabling gene therapy researchers to improve cellular entry and aid gene transfer.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Website
- cathedraltx.com/
- Ownership
- Privately Held (backing)
Cathedral Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cathedral Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cathedral Therapeutics in its N-PORT filings yet. We sweep new filings monthly.